Company Profile
Pharvaris Stock Price, News & Analysis
- Ticker:
- PHVS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
34.45 USD (+3.08%)
Close
Last updated: August 6, 2026
2.03B USD
Market cap
Why the stock is moving
Following the latest company update, “Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology”, PHVS closed up 3.08% at $34.45 on Aug 6, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Oral Bradykinin Therapeutics
Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.
On-Demand Formulation
Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies.
Prophylactic Formulation
Extended-release deucrictibant is designed for prevention of attacks, allowing the same molecule to address both acute and chronic treatment.
Future catalysts
An NDA submission for immediate-release deucrictibant in on-demand hereditary angioedema treatment is planned for the first half of 2026.
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Pharvaris Announces Annual General Meeting of Shareholders
Source: Pharvaris
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pharvaris (PHVS)?
Pharvaris (PHVS) most recently closed at 34.45 USD, a +3.08% move versus the previous session.
What is the market cap of Pharvaris (PHVS)?
Pharvaris currently has a market capitalization of 2.03B USD on BioPharmSignal.
What does Pharvaris do?
Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema. On-Demand Formulation Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies. Prophylactic...
On which exchange is PHVS stock listed?
Pharvaris (PHVS) is associated with NASDAQ, Netherlands, Biopharma.
What is CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
Which conditions is Pharvaris targeting with CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
How does Pharvaris describe recent progress with CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
What is Oral?
Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.